INS and Hypoglycemia: Sulfonylureas or glinides were discontinued (ONWARDS 1, 2, and 4) or the pretrial dose halved (ONWARDS 3 and 5) because of unacceptable gain in the risk of hypoglycemia when combined with basal insulins.